ES2B-C001
- Generic Name
- ES2B-C001
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2 Expressing Metastatic Breast Cancer.
Phase 1
Recruiting
- Conditions
- Breast CancerBreast Cancer Metastatic
- Interventions
- Other: ISA 51 VD
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- ExpreS2ion Biotechnologies
- Target Recruit Count
- 27
- Registration Number
- NCT06746688
- Locations
- 🇦🇹
Medical University Of Vienna, Vienna, Austria
🇦🇹Medical University Of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath